Evidence map›Paper›PMID 42373875›Full record

GuidelineWorld journal of urology2026

What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group.

Selcuk Erdem, Daniele Amparore, Chiara Re, Samed Verep, Umberto Capitanio, Alessandro Larcher, Eduard Roussel, Tobias Klatte, Riccardo Bertolo, Stijn Muselaers and 27 more

Abstract readReviewPractice Guideline
PubMed Publisher
In one paragraph

Guideline in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Selcuk ErdemDivision of Urologic Oncology, Department of Urology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey. erdemselcuk1@gmail.com.ORCID https://orcid.org/0000-0002-3514-1394
Daniele AmparoreDepartment of Oncology, University of Turin, Orbassano, Turin, Italy.
Chiara ReDepartment of Surgery, Cambridge Biomedical Centre, University of Cambridge, Cambridge, UK.
Samed VerepDepartment of Urology, Private Yuzyil Hospital, Istanbul, Kocaeli , Turkey.
Umberto CapitanioUnit of Urology, University Vita-Salute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Alessandro LarcherUnit of Urology, University Vita-Salute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Eduard RousselDepartment of Urology, University Hospitals of Leuven, Leuven, Belgium.
Tobias KlatteDepartment of Urology, Helios Klinikum Bad Saarow, Bad Saarow, Germany.
Riccardo BertoloDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Stijn MuselaersDepartment of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
Nicola PavanDepartment of Surgical, Oncological and Oral Sciences, Section of Urology, University of Palermo, Palermo, Italy.
Onder KaraDepartment of Urology, Kocaeli University School of Medicine, İzmit, Kocaeli, Turkey.
Alexandre IngelsDepartment of Urology, Hôpitaux Universitaires Henri-Mondor, Créteil, France.
Angela PecoraroDivision of Urology, Pederzoli Hospital, Peschiera del Garda, Verona, Italy.
Michele MarchioniDepartment of Medical Oral and Biotechnological Science, Università Degli Studi G. DAnnunzio of Chieti, Chieti, 66100, Italy.
Savio Domenico PandolfoDepartment of Neurosciences and Reproductive Sciences and Odontostomatology, University of Naples, Naples, Italy.
Pietro DianaDepartment of Urology, Fundació Puigvert, Autonoma University of Barcelona, Barcelona, Spain.
Umberto CarbonaraUnit of Andrology and Kidney Transplantation, Department of Emergency and Organ Transplantation-Urology, University of Bari, Bari, Italy.
Veronica MollicaMedical Oncology, IRCCS - Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Hannah WarrenDivision of Surgery and Interventional Science, University College London, London, UK.
Leonardo BorregalesDivision of Urology , Mount Sinai Medical Center, Columbia University, Miami Beach, FL, USA.
Laura MarandinoSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Gopal SharmaUrologic Oncology and Robotic Surgery, Medanta The Medicity, Gurugram, India.
Anna CaliòDepartment of Diagnostic and Public Health, University of Verona, Verona, Italy.
Zhenjie WuDepartment of Urology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Luca Alberto LovatiDepartment of Oncology, University of Turin, Orbassano, Turin, Italy.
Chiara CiccareseDepartment of Medical Oncology, Comprehensive Cancer Center, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy.
Gaëlle MargueUrology Department, Bordeaux University Hospital, Bordeaux, France.
Giulio FrancoliniRadiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Ronan FlippotDepartment of Cancer Medicine, Gustave Roussy, Université Paris Saclay, L.I.O, CNRS 3655 and INSERM US 23 AMMICA, Villejuif, France.
David Kawai LeungDivision of Urology, S H Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Sha Tin, Hong Kong, China.
Georges MjaessDepartment of Urology, Hopital Universitaire de Bruxelles, Universitè Libre de Bruxelles, Bruxelles, Belgium.
Giuseppe RosielloIRCCS San Raffaele Scientific Institute, Urological Research Institute (URI), University Vita-Salute San Raffaele, Milan, Italy.
Maria Carme MirDepartment of Urology, Mount Sinai Icahn School of Medicine, Elmhurst/Queens Hospital, New York, USA.
Carlotta PalumboUnit of Urology, Maggiore della Carità Hospital, Novara, Italy.
Riccardo CampiUrological Robotic Surgery and Renal Transplantation Unit, Department of Experimental and Clinical Medicine Careggi Hospital, University of Florence, Florence, Italy.
EAU-YAU Renal Cancer Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveRenal cell carcinoma (RCC) is a common manifestation in Von-Hippel Lindau (VHL) syndrome, accounting for almost 30% of the patients. However, since VHL syndrome is relatively rare, there are no clear guidelines regarding the approach to VHL patients with RCC. This article aims to provide evidence-based insights for diagnosis, treatment, and surveillance in VHL patients with RCC.

methodsThe articles indexed between 1977 and 2025 in PubMed was searched. Only articles in English were included.

resultsRenal cysts are quite common in VHL patients and these cysts predispose for RCC. VHL patients are characterized with early-onset, multifocal and/or bilateral, recurrent and clear cell subtype RCC. Patients should be monitored at regular intervals. Due to recurrent characteristics of RCC, nephron-sparing surgeries should be prioritized with the aim of life-long kidney function preservation, whenever it is feasible. Focal treatments should be considered in patients for whom surgery is not suitable. In addition, belzutifan treatment has shown promising results in selected patients.

conclusionIn VHL patients with RCC, kidney function should be preserved whenever possible to ensure a long and high-quality life. Since these patients may develop lesions in other organs beyond kidney, surveillance with multidisciplinary approach in tertiary centers should be recommended.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsUrologyvon Hippel-Lindau DiseaseHumansNephron sparing surgeryRenal cell carcinomaSurveillanceTargeted therapyVon-Hippel Lindau

Identifiers

PMID42373875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.